Author

T. Varila

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1

Frequent Co-Authors

E. Loyttyniemi· 2 shared E. Makela· 2 shared J. Westermarck· 2 shared M. Itala-Remes· 2 shared U. Salmenniemi· 2 shared A. K. Najumudeen· 1 shared C. Lucas· 1 shared D. Abankwa· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Loyttyniemi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting a broad spectrum of KRAS-mutant cancers by hyperactivation-induced cell death

J. Lilja, J. Kaivola, J. R. W. Conway, J. Vuorio, H. Parkkola, P. Roivas, T. Varila, G. Jacquemet, E. Peuhu, E. Wang, U. Pentikäinen, I. M. D. Posada, H. Hamidi, A. K. Najumudeen, O. J. Sansom, , J. Ivaska

This study identifies SHANK3 as a RAS interactor that limits oncogenic KRAS signaling, and shows that disrupting its interaction with KRAS induces cell death in KRAS-mutant cancers.

bioRxiv · Sep 21, 2022 · PreprintCancer Biology

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

E. Makela, K. Pavic, T. Varila, U. Salmenniemi, E. Loyttyniemi, S. Nagelli, V.-M. Kahari, R. E. Clark, V. K. Bachanaboyina, C. Lucas, M. Itala-Remes, J. Westermarck

The paper discovers a novel CIP2A splicing variant, NOCIVA, which is overexpressed in myeloid leukemias and correlates with poor clinical outcomes.

bioRxiv · Aug 24, 2020Cancer Biology

ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia

E. Makela, E. Loyttyniemi, U. Salmenniemi, O. Kauko, T. Varila, V. Kairisto, M. Itala-Remes, J. Westermarck

This study identifies ARPP19 as an oncogenic PP2A inhibitor in AML that predicts relapse independently of risk classification and is associated with disease activity.

bioRxiv · Jul 5, 2019Cancer Biology